Treatment of Severe Idiopathic Mixed Autoimmune Hemolytic Anemia

2317 words (9 pages) Essay

8th Feb 2020 Medical Reference this

Disclaimer: This work has been submitted by a university student. This is not an example of the work produced by our Essay Writing Service. You can view samples of our professional work here.

Any opinions, findings, conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of UKEssays.com.

SUCCESSFUL TREATMENT OF SEVERE IDIOPATHIC MIXED AUTOIMMUNE HEMOLYTIC ANEMIA WITH BORTEZOMIB AND INTRAVENOUS IMMUNOGLOBULIN

ABSTRACT

Introduction

Autoimmune hemolytic anemia (AIHA) is a rare and diverse group of acquired hemolytic anemias which results from increased destruction of red blood cells (RBC) due to autoantibodies directed against antigens on the RBC surface. Currently, there are no clearly defined evidence-based guidelines on the management of AIHA and current treatment options are based on small retrospective studies, case reports as well as expert experiences and recommendations. We report a case of severe idiopathic mixed AIHA that responded to a combination of steroids, intravenous immunoglobulin (IVIG) and bortezomib.

Case Presentation

A 25-year-old African American female presented with jaundice, shortness of breath and abdominal pain. She had splenomegaly on examination and labs were significant for severe anemia (hemoglobin, 3.3) and hyperbilirubinemia (total bilirubin, 26.7; direct bilirubin, 21.9). Direct antiglobulin test (DAT) was microscopically positive for anti-IgG and anti-C3d, and cold autoantibodies were identified. An extensive workup for a possible secondary cause of her anemia was non-revealing. She was sequentially treated with prednisone, IVIG and bortezomib. Tremendous resolution of the hemolysis was achieved with improvement in the hemoglobin from a nadir of 3.2 on admission to 10.1 at discharge. Patient has remained clinically in remission since then.

Conclusion

The first line treatment for warm AIHA (w-AIHA) includes glucocorticoids and transfusion of least incompatible RBCs. But steroids are rarely necessary or effective in cold agglutinin AIHA in which case high dose IVIG and plasmapheresis have been used albeit with inconsistent results. Bortezomib is an inhibitor of the 26S proteasome and is approved for the treatment of multiple myeloma. It has been reported to have some activity in rituximab-resistant cold agglutinin disease (CAD) due to its activity against the CD20-negative plasma cell compartment that may be responsible for IgG anti-RBC autoantibody production.

Introduction

Autoimmune hemolytic anemia (AIHA) results from increased RBC destruction caused by autoantibodies reacting against RBC antigens with or without complement activation1. The clinical presentation depends on the subclass type (warm agglutinin, cold agglutinin, and mixed type); a classification based on the thermal amplitude of the causative autoantibody. Mixed AIHA is an unusual and rarely reported type of AIHA in which the laboratory data satisfy the serologic criteria of both w-AIHA and CAD1. The rarity of this form of AIHA presents a therapeutic challenge as the class and characteristics of the causative autoantibody play a role in the patient’s treatment and outcome2. Equally imperative to treatment outcomes is the need to determine the etiology of AIHA as over 50% of cases are secondary to a number of infectious, neoplastic and autoimmune disorders3 where a resolution of symptoms can be achieved with the treatment of the underlying etiology. Therapeutic options for the treatment of hemolysis associated with mixed AIHA are limited4 as it is associated with a more severe disease course. Herein, we present the case of a patient in whom resolution of hemolysis and improvement in hemoglobin count was achieved following sequential treatment with steroids, IVIG and bortezomib. 

Case Description

A 25-year-old female visiting from Out-of-State presented to the Emergency Department (ED) with abdominal pain, shortness of breath, vomiting and subjective fevers. She had previously been investigated for abdominal pain about 7 months prior to current presentation. At that time, she was informed of some problems with her liver and asked to return to the clinic but was lost to follow-up. The patient did not have any other significant past medical history and was not taking any regular medications.

Get Help With Your Essay

If you need assistance with writing your essay, our professional essay writing service is here to help!

Find out more

Her vital signs were stable except for sinus tachycardia of 143 beats/min. Physical examination revealed pallor, deep jaundice, and mild splenomegaly. Laboratory findings included anemia (hemoglobin 3.3 g/dl and hematocrit 10.2), elevated bilirubin (total bilirubin 26.7 and direct bilirubin 21.9) and elevated lactate dehydrogenase (LDH) of 193 U/l. White cell and platelet counts were normal. Direct Coombs test (anti-IgG and anti-C3) was positive and cold-reactive autoantibodies were identified and the titer was reported as high but not given in the report. Computed tomography (CT) scan of the abdomen showed splenomegaly.

Infectious mononucleosis, cytomegalovirus, parvovirus, syphilis, mycoplasma pneumonia, systemic lupus erythematosus, and human immunodeficiency virus were all ruled out. Blood, urine and sputum cultures were negative. Antinuclear antibody (ANA) immunofluorescence assay was initially positive but subsequent ANA screen was negative. This was attributed to the intravenous immunoglobulin she received. Screening for Wilson’s disease and hemochromatosis were also negative.  Subsequently, fine needle aspiration biopsy of an axillary lymph node was performed and this revealed benign lymphoid cells. Flow cytometry for leukemia/lymphoma panel detected no clonal B-cell or atypical T-cell population.

Due to the antibody load in her blood, the blood bank sent her sample to the Red Cross Reference laboratory to find the least incompatible blood for her. She was transfused several units during her hospital course. The Hematology service was consulted and a diagnosis of mixed type autoimmune hemolytic anemia was made. Thus, the patient was given a loading dose of intravenous methylprednisolone 125 mg once, followed by oral prednisone 100 mg daily. Simultaneously, she was started on intravenous immune globulin 100 g daily for 2 doses. In spite of the above therapy, the patient’s hemoglobin and clinical status did not improve substantially and she continued to require almost daily blood transfusions. Based on anecdotal isolated reports of the efficacy of bortezomib in autoimmune hemolytic anemia, our patient was started on bortezomib 2.7 mg every 72 hours and got a total of 4 doses. Following the first two courses of bortezomib, the patient showed a remarkable clinical improvement. Her hemoglobin levels started trending up and she no longer required blood transfusions. Markers of acute hemolysis like lactate dehydrogenase, bilirubin levels, and reticulocyte count also dropped progressively. Subsequently, the prednisone was gradually tapered.  At discharge, her hemoglobin was 10.1 (figure 1), total bilirubin 5.2 (figure 2) and direct bilirubin 2.3. A follow-up call to her Hematologist at the facility where she follows up in her home state 1-month post discharge confirmed that she has remained in remission and hemoglobin levels have remained stable.

Figure 1 showing the trend of hemoglobin from admission to discharge.

Figure 2 showing the decline in total bilirubin following the initiation of treatment.

 

Discussion

Diagnosis of mixed AIHA is based on the detection of autoantibodies by monospecific direct antiglobulin test (DAT) showing a pattern of IgG, complement C3d and presence of cold agglutinins5 which are mostly of the IgM class. It is a rare diagnosis, comprising < 5% of reported cases of AIHA. Based on our patient’s clinical presentation, laboratory analysis and absence of an obvious secondary etiology after an extensive workup, she meets the criteria for idiopathic or primary mixed autoimmune hemolytic anemia.

Find out how UKEssays.com can help you!

Our academic experts are ready and waiting to assist with any writing project you may have. From simple essay plans, through to full dissertations, you can guarantee we have a service perfectly matched to your needs.

View our services

The standard therapeutic approaches to the treatment of autoimmune hemolytic anemia include corticosteroids, splenectomy, immunosuppressive agents and monoclonal antibodies3, the most reported of which is rituximab. Rituximab is a potent anti-CD20 monoclonal antibody that destroys B lymphocytes via complement activation and has been used in the management of patients with cold agglutinin disease with severe hemolysis that has not responded to conventional therapy. However, the effect of treatment with rituximab is unpredictable and is usually not abrupt2. Khandelwal et al hypothesized that autoimmune cytopenias become refractory because current therapies do not target autoreactive plasma cells, and outcomes can be improved with plasma cell agents6 such as bortezomib.

Bortezomib is an inhibitor of the 26S proteasome, a large protease complex that degrades ubiquitinated proteins and is approved for the treatment of multiple myeloma and mantle cell lymphoma in the United States7. By blocking the targeted proteolysis usually performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. In contrast to rituximab, which targets CD20 B lymphocytes, bortezomib targets differentiated plasma cells that typically do not express CD20 but may be responsible for secretion of the abnormal IgM responsible for hemolysis in CAD8. Moreover, chronic inflammatory processes in autoimmune diseases can be sustained by long-lived plasma cells which continuously secrete pathogenic antibodies.  Proteasome inhibitors that target plasma cells like bortezomib could effectively weaken this antibody-producing category of cells. In view of its effect on malignant B cells and plasma cells, bortezomib has been used to treat other plasma cell disorders, with case reports of successful treatment of immune hemolytic anemia related to cryoglobulinemia, systemic lupus erythematosus, and myasthenia gravis9. Danchaivijitr et al reported that a combination of bortezomib and low-dose cyclophosphamide was successfully used to treat a patient with transfusion-dependent and steroid/rituximab-refractory AIHA6.

The combined use of prednisone, IVIG and bortezomib in our patient leading to her successful therapeutic outcome may make it difficult to discern which components of the combination therapy were responsible for the improvement in the hemolytic process. However, it is noteworthy that the observed sustained improvement in her hemoglobin level was noticed only after the introduction of bortezomib. Although steroids suppress antibody production and down‐regulate Fc‐receptor‐mediated red cell destruction in the spleen, reports indicate that their effect is not immediate and often takes 2-4 weeks to manifest10. Also, the effectiveness of high dose intravenous immunoglobulin has been more pronounced in children with AIHA secondary to infections rather than adults with idiopathic disease2.

Conclusion

Despite the availability of multiple therapeutic modalities, autoimmune hemolytic anemias especially the mixed type can be refractory to such interventions. Based on our experience with our patient and other reported cases, further research is imperative to further explore the potential therapeutic effects of bortezomib in nonmalignant disorders, including autoimmune hemolytic anemias.

References

  1. Kalfa TA: Warm antibody autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2016 Dec 2, 2016(1): 690-697.
  2. Abdulgabar Salama: Treatment options for primary autoimmune hemolytic anemia: A short comprehensive review. Transfus Med Hemother 2015;42:294-301.
  3. Bass GF, Tuscano ET, et al: Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev. 2014 Apr–May; 13(4-5): 560-4.
  4. Gupta S, Szerszen A, et al: Severe refractory autoimmune hemolytic anemia with both warm and cold autoantibodies that responded completely to a single cycle of rituximab: A case report. J Med Case Rep. 2011 Apr 19;5:156.
  5. Sudha VR, Samayam P, et al: Autoimmune Hemolytic Anemia: Mixed Type – A Case Report. Indian J Hematol Blood Transfus. 2011 Jun; 27(2): 107-110.
  6. Khandelwal P, Davies SM, et al: Bortezomib for refractory autoimmunity in pediatrics. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1654-9.
  7. Danchaivijitr P, Yared J: Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide. Am J Hematol. 2011 Mar; 86(3):331-2.
  8. Carson KR, Beckwith LG, et al: Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood. 2010 Jan 28; 115(4):915.
  9. Hosoba S, Jaye DL, et al: Successful treatment of severe immune hemolytic anemia after allogenic stem cell transplantation with bortezomib: Report of a case and Review of literature. Transfusion. 2015 Feb; 55(2): 259-264.
  10. George G, Petz LD, et al: The correlation of cold agglutinin titrations in saline and albumin with hemolytic anemia. Br J of Hematol. 1977 Apr; 35(4):587-95.

 

SUCCESSFUL TREATMENT OF SEVERE IDIOPATHIC MIXED AUTOIMMUNE HEMOLYTIC ANEMIA WITH BORTEZOMIB AND INTRAVENOUS IMMUNOGLOBULIN

ABSTRACT

Introduction

Autoimmune hemolytic anemia (AIHA) is a rare and diverse group of acquired hemolytic anemias which results from increased destruction of red blood cells (RBC) due to autoantibodies directed against antigens on the RBC surface. Currently, there are no clearly defined evidence-based guidelines on the management of AIHA and current treatment options are based on small retrospective studies, case reports as well as expert experiences and recommendations. We report a case of severe idiopathic mixed AIHA that responded to a combination of steroids, intravenous immunoglobulin (IVIG) and bortezomib.

Case Presentation

A 25-year-old African American female presented with jaundice, shortness of breath and abdominal pain. She had splenomegaly on examination and labs were significant for severe anemia (hemoglobin, 3.3) and hyperbilirubinemia (total bilirubin, 26.7; direct bilirubin, 21.9). Direct antiglobulin test (DAT) was microscopically positive for anti-IgG and anti-C3d, and cold autoantibodies were identified. An extensive workup for a possible secondary cause of her anemia was non-revealing. She was sequentially treated with prednisone, IVIG and bortezomib. Tremendous resolution of the hemolysis was achieved with improvement in the hemoglobin from a nadir of 3.2 on admission to 10.1 at discharge. Patient has remained clinically in remission since then.

Conclusion

The first line treatment for warm AIHA (w-AIHA) includes glucocorticoids and transfusion of least incompatible RBCs. But steroids are rarely necessary or effective in cold agglutinin AIHA in which case high dose IVIG and plasmapheresis have been used albeit with inconsistent results. Bortezomib is an inhibitor of the 26S proteasome and is approved for the treatment of multiple myeloma. It has been reported to have some activity in rituximab-resistant cold agglutinin disease (CAD) due to its activity against the CD20-negative plasma cell compartment that may be responsible for IgG anti-RBC autoantibody production.

Introduction

Autoimmune hemolytic anemia (AIHA) results from increased RBC destruction caused by autoantibodies reacting against RBC antigens with or without complement activation1. The clinical presentation depends on the subclass type (warm agglutinin, cold agglutinin, and mixed type); a classification based on the thermal amplitude of the causative autoantibody. Mixed AIHA is an unusual and rarely reported type of AIHA in which the laboratory data satisfy the serologic criteria of both w-AIHA and CAD1. The rarity of this form of AIHA presents a therapeutic challenge as the class and characteristics of the causative autoantibody play a role in the patient’s treatment and outcome2. Equally imperative to treatment outcomes is the need to determine the etiology of AIHA as over 50% of cases are secondary to a number of infectious, neoplastic and autoimmune disorders3 where a resolution of symptoms can be achieved with the treatment of the underlying etiology. Therapeutic options for the treatment of hemolysis associated with mixed AIHA are limited4 as it is associated with a more severe disease course. Herein, we present the case of a patient in whom resolution of hemolysis and improvement in hemoglobin count was achieved following sequential treatment with steroids, IVIG and bortezomib. 

Case Description

A 25-year-old female visiting from Out-of-State presented to the Emergency Department (ED) with abdominal pain, shortness of breath, vomiting and subjective fevers. She had previously been investigated for abdominal pain about 7 months prior to current presentation. At that time, she was informed of some problems with her liver and asked to return to the clinic but was lost to follow-up. The patient did not have any other significant past medical history and was not taking any regular medications.

Her vital signs were stable except for sinus tachycardia of 143 beats/min. Physical examination revealed pallor, deep jaundice, and mild splenomegaly. Laboratory findings included anemia (hemoglobin 3.3 g/dl and hematocrit 10.2), elevated bilirubin (total bilirubin 26.7 and direct bilirubin 21.9) and elevated lactate dehydrogenase (LDH) of 193 U/l. White cell and platelet counts were normal. Direct Coombs test (anti-IgG and anti-C3) was positive and cold-reactive autoantibodies were identified and the titer was reported as high but not given in the report. Computed tomography (CT) scan of the abdomen showed splenomegaly.

Infectious mononucleosis, cytomegalovirus, parvovirus, syphilis, mycoplasma pneumonia, systemic lupus erythematosus, and human immunodeficiency virus were all ruled out. Blood, urine and sputum cultures were negative. Antinuclear antibody (ANA) immunofluorescence assay was initially positive but subsequent ANA screen was negative. This was attributed to the intravenous immunoglobulin she received. Screening for Wilson’s disease and hemochromatosis were also negative.  Subsequently, fine needle aspiration biopsy of an axillary lymph node was performed and this revealed benign lymphoid cells. Flow cytometry for leukemia/lymphoma panel detected no clonal B-cell or atypical T-cell population.

Due to the antibody load in her blood, the blood bank sent her sample to the Red Cross Reference laboratory to find the least incompatible blood for her. She was transfused several units during her hospital course. The Hematology service was consulted and a diagnosis of mixed type autoimmune hemolytic anemia was made. Thus, the patient was given a loading dose of intravenous methylprednisolone 125 mg once, followed by oral prednisone 100 mg daily. Simultaneously, she was started on intravenous immune globulin 100 g daily for 2 doses. In spite of the above therapy, the patient’s hemoglobin and clinical status did not improve substantially and she continued to require almost daily blood transfusions. Based on anecdotal isolated reports of the efficacy of bortezomib in autoimmune hemolytic anemia, our patient was started on bortezomib 2.7 mg every 72 hours and got a total of 4 doses. Following the first two courses of bortezomib, the patient showed a remarkable clinical improvement. Her hemoglobin levels started trending up and she no longer required blood transfusions. Markers of acute hemolysis like lactate dehydrogenase, bilirubin levels, and reticulocyte count also dropped progressively. Subsequently, the prednisone was gradually tapered.  At discharge, her hemoglobin was 10.1 (figure 1), total bilirubin 5.2 (figure 2) and direct bilirubin 2.3. A follow-up call to her Hematologist at the facility where she follows up in her home state 1-month post discharge confirmed that she has remained in remission and hemoglobin levels have remained stable.

Figure 1 showing the trend of hemoglobin from admission to discharge.

Figure 2 showing the decline in total bilirubin following the initiation of treatment.

 

Discussion

Diagnosis of mixed AIHA is based on the detection of autoantibodies by monospecific direct antiglobulin test (DAT) showing a pattern of IgG, complement C3d and presence of cold agglutinins5 which are mostly of the IgM class. It is a rare diagnosis, comprising < 5% of reported cases of AIHA. Based on our patient’s clinical presentation, laboratory analysis and absence of an obvious secondary etiology after an extensive workup, she meets the criteria for idiopathic or primary mixed autoimmune hemolytic anemia.

The standard therapeutic approaches to the treatment of autoimmune hemolytic anemia include corticosteroids, splenectomy, immunosuppressive agents and monoclonal antibodies3, the most reported of which is rituximab. Rituximab is a potent anti-CD20 monoclonal antibody that destroys B lymphocytes via complement activation and has been used in the management of patients with cold agglutinin disease with severe hemolysis that has not responded to conventional therapy. However, the effect of treatment with rituximab is unpredictable and is usually not abrupt2. Khandelwal et al hypothesized that autoimmune cytopenias become refractory because current therapies do not target autoreactive plasma cells, and outcomes can be improved with plasma cell agents6 such as bortezomib.

Bortezomib is an inhibitor of the 26S proteasome, a large protease complex that degrades ubiquitinated proteins and is approved for the treatment of multiple myeloma and mantle cell lymphoma in the United States7. By blocking the targeted proteolysis usually performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. In contrast to rituximab, which targets CD20 B lymphocytes, bortezomib targets differentiated plasma cells that typically do not express CD20 but may be responsible for secretion of the abnormal IgM responsible for hemolysis in CAD8. Moreover, chronic inflammatory processes in autoimmune diseases can be sustained by long-lived plasma cells which continuously secrete pathogenic antibodies.  Proteasome inhibitors that target plasma cells like bortezomib could effectively weaken this antibody-producing category of cells. In view of its effect on malignant B cells and plasma cells, bortezomib has been used to treat other plasma cell disorders, with case reports of successful treatment of immune hemolytic anemia related to cryoglobulinemia, systemic lupus erythematosus, and myasthenia gravis9. Danchaivijitr et al reported that a combination of bortezomib and low-dose cyclophosphamide was successfully used to treat a patient with transfusion-dependent and steroid/rituximab-refractory AIHA6.

The combined use of prednisone, IVIG and bortezomib in our patient leading to her successful therapeutic outcome may make it difficult to discern which components of the combination therapy were responsible for the improvement in the hemolytic process. However, it is noteworthy that the observed sustained improvement in her hemoglobin level was noticed only after the introduction of bortezomib. Although steroids suppress antibody production and down‐regulate Fc‐receptor‐mediated red cell destruction in the spleen, reports indicate that their effect is not immediate and often takes 2-4 weeks to manifest10. Also, the effectiveness of high dose intravenous immunoglobulin has been more pronounced in children with AIHA secondary to infections rather than adults with idiopathic disease2.

Conclusion

Despite the availability of multiple therapeutic modalities, autoimmune hemolytic anemias especially the mixed type can be refractory to such interventions. Based on our experience with our patient and other reported cases, further research is imperative to further explore the potential therapeutic effects of bortezomib in nonmalignant disorders, including autoimmune hemolytic anemias.

References

  1. Kalfa TA: Warm antibody autoimmune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2016 Dec 2, 2016(1): 690-697.
  2. Abdulgabar Salama: Treatment options for primary autoimmune hemolytic anemia: A short comprehensive review. Transfus Med Hemother 2015;42:294-301.
  3. Bass GF, Tuscano ET, et al: Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev. 2014 Apr–May; 13(4-5): 560-4.
  4. Gupta S, Szerszen A, et al: Severe refractory autoimmune hemolytic anemia with both warm and cold autoantibodies that responded completely to a single cycle of rituximab: A case report. J Med Case Rep. 2011 Apr 19;5:156.
  5. Sudha VR, Samayam P, et al: Autoimmune Hemolytic Anemia: Mixed Type – A Case Report. Indian J Hematol Blood Transfus. 2011 Jun; 27(2): 107-110.
  6. Khandelwal P, Davies SM, et al: Bortezomib for refractory autoimmunity in pediatrics. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1654-9.
  7. Danchaivijitr P, Yared J: Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide. Am J Hematol. 2011 Mar; 86(3):331-2.
  8. Carson KR, Beckwith LG, et al: Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood. 2010 Jan 28; 115(4):915.
  9. Hosoba S, Jaye DL, et al: Successful treatment of severe immune hemolytic anemia after allogenic stem cell transplantation with bortezomib: Report of a case and Review of literature. Transfusion. 2015 Feb; 55(2): 259-264.
  10. George G, Petz LD, et al: The correlation of cold agglutinin titrations in saline and albumin with hemolytic anemia. Br J of Hematol. 1977 Apr; 35(4):587-95.

 

Cite This Work

To export a reference to this article please select a referencing stye below:

Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.

Related Services

View all

DMCA / Removal Request

If you are the original writer of this essay and no longer wish to have your work published on the UKDiss.com website then please: